ESMO-话题@MedSci

#ESMO#

214篇内容 | 4999人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2205706, encodeId=28c82205e064b, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a> <a href='/topic/show?id=785545324fd' target=_blank style='color:#2F92EE;'>#孕酮受体#</a>, objectTitle=2024 ESMO BC | 孕酮受体状态在ER阴性乳腺癌中的预后作用及化疗对其生存率的影响, objectType=article, longId=825971, objectId=51088259e1de, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240520/1716191247081_5579292.jpg, objectUrl=/article/show_article.do?id=51088259e1de, replyNumber=0, likeNumber=73, createdTime=2024-05-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=51088259e1de, moduleTitle=2024 ESMO BC | 孕酮受体状态在ER阴性乳腺癌中的预后作用及化疗对其生存率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51088259e1de)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175112, encodeId=d91a21e511221, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a> <a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三阴性乳腺癌#</a> <a href='/topic/show?id=c3f910342343' target=_blank style='color:#2F92EE;'>#鼻咽癌#</a> <a href='/topic/show?id=bacf291496a' target=_blank style='color:#2F92EE;'>#免疫肿瘤学#</a>, objectTitle=2023 ESMO IO｜早期治疗的免疫肿瘤学探索, objectType=article, longId=805052, objectId=296180505267, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=296180505267, replyNumber=0, likeNumber=108, createdTime=2023-12-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=296180505267, moduleTitle=2023 ESMO IO｜早期治疗的免疫肿瘤学探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=296180505267)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2164864, encodeId=8ee5216486473, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>：这次会议将对肺癌领域的多项研究数据进行更新和展示。特别是针对<a href='/topic/show?id=94c265920c' target=_blank style='color:#2F92EE;'>#EGFR突变#</a>阳性非小细胞肺癌（<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>）的靶向治疗，将成为备受关注的焦点。随着EGFR酪氨酸激酶抑制剂（<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>）的研发成功，一代/二代/三代EGFR-TKI已经被批准上市用于EGFR突变的晚期NSCLC治疗，<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>是唯一具有确切总生存期（<a href='/topic/show?id=3bf913489f4' target=_blank style='color:#2F92EE;'>#OS#</a>）数据的三代EGFR-TKI药物。, objectTitle=2023 ESMO |【奥希替尼】一线治疗地位无可撼动，新方案带来更多惊喜！, objectType=article, longId=797861, objectId=a343e978611e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20231023/7e658cfe5226459cbf06b6d0e070b22e.jpg, objectUrl=/article/show_article.do?id=a343e978611e, replyNumber=0, likeNumber=141, createdTime=2023-10-25, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a343e978611e, moduleTitle=2023 ESMO |【奥希替尼】一线治疗地位无可撼动，新方案带来更多惊喜！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a343e978611e)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1281092, encodeId=3c86128109208, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, objectType=article, longId=739183, objectId=460ce39183f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=460ce39183f7, replyNumber=0, likeNumber=130, createdTime=2022-09-15, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=460ce39183f7, moduleTitle=Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=460ce39183f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281091, encodeId=c26e1281091b0, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022会议精萃, objectType=article, longId=739084, objectId=df47e3908432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df47e3908432, replyNumber=0, likeNumber=112, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df47e3908432, moduleTitle=ESMO 2022会议精萃, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df47e3908432)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281090, encodeId=40b4128109005, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, objectType=article, longId=739082, objectId=0c30e3908258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c30e3908258, replyNumber=0, likeNumber=97, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c30e3908258, moduleTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c30e3908258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281089, encodeId=c0b7128108991, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：CAR-T治疗用于实体瘤研究发布多项重要研究成果！, objectType=article, longId=739081, objectId=ec8be39081d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8be39081d7, replyNumber=0, likeNumber=107, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8be39081d7, moduleTitle=ESMO 2022：CAR-T治疗用于实体瘤研究发布多项重要研究成果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8be39081d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281088, encodeId=35611281088cf, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, objectType=article, longId=739080, objectId=9bbfe3908038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bbfe3908038, replyNumber=0, likeNumber=88, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bbfe3908038, moduleTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bbfe3908038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281087, encodeId=eb4c128108e1d, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, objectType=article, longId=739079, objectId=dbbfe390796d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbbfe390796d, replyNumber=0, likeNumber=100, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbbfe390796d, moduleTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbbfe390796d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281086, encodeId=ae381281086e5, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：T-DXd治疗乳腺癌不仅能提高生存，还能改善生活质量（DESTINY-Breast04研究）, objectType=article, longId=739078, objectId=084fe3907869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=084fe3907869, replyNumber=0, likeNumber=102, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=084fe3907869, moduleTitle=ESMO 2022：T-DXd治疗乳腺癌不仅能提高生存，还能改善生活质量（DESTINY-Breast04研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=084fe3907869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281085, encodeId=d7581281085f6, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, objectType=article, longId=739077, objectId=6949e390775b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6949e390775b, replyNumber=0, likeNumber=119, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6949e390775b, moduleTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6949e390775b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281084, encodeId=7e17128108456, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=145, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281083, encodeId=23851281083d7, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, objectType=article, longId=739075, objectId=1b78e39075cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b78e39075cc, replyNumber=0, likeNumber=92, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b78e39075cc, moduleTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b78e39075cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281082, encodeId=afac1281082c0, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=87, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281081, encodeId=330c128108152, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, objectType=article, longId=739073, objectId=814ce3907329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=814ce3907329, replyNumber=0, likeNumber=93, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=814ce3907329, moduleTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=814ce3907329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281080, encodeId=6c2e12810800f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, objectType=article, longId=739072, objectId=0c76e39072d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c76e39072d5, replyNumber=0, likeNumber=82, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c76e39072d5, moduleTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c76e39072d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281078, encodeId=c18e12810e8ea, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, objectType=article, longId=739071, objectId=dd97e3907119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd97e3907119, replyNumber=0, likeNumber=114, createdTime=2022-09-13, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd97e3907119, moduleTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd97e3907119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281079, encodeId=d16412810e997, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2022：创新药物、创新疗法，精彩荟萃, objectType=article, longId=738627, objectId=a5c6e3862703, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c6e3862703, replyNumber=0, likeNumber=104, createdTime=2022-09-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c6e3862703, moduleTitle=ESMO 2022：创新药物、创新疗法，精彩荟萃, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5c6e3862703)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281077, encodeId=c94112810e7fe, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！, objectType=article, longId=737089, objectId=21f9e37089c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21f9e37089c5, replyNumber=0, likeNumber=115, createdTime=2022-08-28, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21f9e37089c5, moduleTitle=ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21f9e37089c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281076, encodeId=ae6f12810e697, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, objectType=article, longId=736795, objectId=5afee36795cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5afee36795cd, replyNumber=0, likeNumber=108, createdTime=2022-08-25, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5afee36795cd, moduleTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5afee36795cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #ESMO# #孕酮受体#

2024 ESMO BC | 孕酮受体状态在ER阴性乳腺癌中的预后作用及化疗对其生存率的影响

2024-05-20发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#ESMO# #三阴性乳腺癌# #鼻咽癌# #免疫肿瘤学#

2023 ESMO IO｜早期治疗的免疫肿瘤学探索

2023-12-15发表于上海

(审核中...)

前往app查看评论内容

全文收起 #ESMO#：这次会议将对肺癌领域的多项研究数据进行更新和展示。特别是针对#EGFR突变#阳性非小细胞肺癌（#NSCLC#）的靶向治疗，将成为备受关注的焦点。随着EGFR酪氨酸激酶抑制剂（#TKI#）的研发成功，一代/二代/三代EGFR-TKI已经被批准上市用于EGFR突变的晚期NSCLC治疗，#奥希替尼#是唯一具有确切总生存期（#OS#）数据的三代EGFR-TKI药物。

2023 ESMO |【奥希替尼】一线治疗地位无可撼动，新方案带来更多惊喜！

2023-10-25发表于上海

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

Rhizen Pharmaceuticals AG宣布即将在ESMO 2022上展示其临床阶段的资产数据；Tenalisib治疗局部晚期/转移性乳腺癌和RP12146治疗多种实体瘤

2022-09-15

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022会议精萃

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：CAR-T治疗用于实体瘤研究发布多项重要研究成果！

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：T-DXd治疗乳腺癌不仅能提高生存，还能改善生活质量（DESTINY-Breast04研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）

2022-09-13

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO 2022：创新药物、创新疗法，精彩荟萃

2022-09-10

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！

2022-08-28

zhang92560 (审核中...)

前往app查看评论内容

#ESMO#

ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）

2022-08-25

科室
- - 订阅+
  - 更多科室
工具
服务